Safety of routine childhood vaccinations: An epidemiological review

Paediatric Drugs

Volumn 2, Issue 4, 2000, Pages 273-290

  Chen, R T ^a   Mootrey, G ^a   DeStefano, F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; VACCINE;

ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ASEPTIC MENINGITIS; BRAIN DISEASE; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; LYMPHADENOPATHY; MUSCLE HYPOTONIA; PAROTITIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SHOCK; SUDDEN INFANT DEATH SYNDROME; THROMBOCYTOPENIA;

EID: 0033871142     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200002040-00004     Document Type: Review

References (158)

1. Progress toward global poliomyelitis eradication 1997-1998
2. The vaccine adverse event reporting system (VAERS)
3. Is infant immunization a risk factor for childhood asthma or allergy?
4. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and regressive developmental disorder in children
5. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus
6. Sclerose en plaques et vaccination contre le virus de l'hepatite B
7. The complicated task of monitoring vaccine safety
8. Safety of vaccines
9. Impact of the anti-vaccine movements on pertussis control: The untold story
10. Association between hepatatis B vaccine and multiple sclerosis: A case-control study
11. Sentinel surveillance shows small decline in MMR coverage
12. Pertussis vaccine trials
13. IgE levels of infants with complications after pertussis vaccination
14. A 7 year survey of disorders attributed to vaccination in North West Thames region
15. Update: Vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices
16. Measles, mumps, and rubella: Vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
17. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines
18. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination: A report on 23 patients
19. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella
20. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991: Implications for estimating the risk of vaccine-associated disease
21. Vaccination of adults with Wistar RA 27/3 rubella vaccine
22. A controlled comparison of joint reactions among women receiving one of two rubella vaccines
23. The vaccine safety datalink project: A new tool for improving vaccine safety monitoring in the United States
24. Special methodological issues in pharmacoepidemiology studies of vaccine safety
25. Pertussis and the vaccine controversy
26. Temporal relationship modeling: DTP or DT immunizations and infantile spasms
27. DPT vaccine and chronic nervous system dysfunction: A new analysis
28. The risk of Guillain-Barre syndrome after tetanus-toxoid containing vaccines in adults and children
29. Pertussis immunisation and serious acute neurological illness in children
30. Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976-1977
31. Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
32. The safety of acellular pertussis vaccine versus whole cell pertussis vaccine: A post-marketing assessment
33. Acellular pertussis vaccines: Towards an improved safety profile
34. Surveillance of vaccine-related adverse events in the first year of life: A Manitoba cohort study
35. Seizures following DPT or MMR vaccination among neurologically impaired or at-risk children: Results from the vaccine safety datalink study
36. Seizures following DPT or MMR vaccination among a cohort of neurologically impaired or at-risk children: Results from the vaccine safety datalink study
37. Infantile spasms and pertussis immunization
38. Relationship of pertussis immunization to the onset of neurologic disorders: A retrospective epidemiologic study
39. Report of a US public health service workshop on hypotonic-hyporesponsive episode (HHE) after pertussis immunization
40. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: Follow up study
41. Pertussis immunisation and serious acute neurological illnesses in children
42. Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome
43. Sudden infant death syndrome and diphtheria-tetanus-pertussis-poliomyelitis vaccination status
44. Diphtheria-tetanuspertussis immunization and sudden infant death: Results of the national institute of child health and human development cooperative epidemiological study of sudden infant death syndrome risk factors
45. Risk of sudden infant death syndrome (SIDS) after immunization with the diphtheria-tetanus-pertussis vaccine
46. Sudden infant death and immunization: An extensive epidemiological approach to the problem in France - Winter 1986
47. Immunisation and the sudden infant death syndrome: New Zealand Cot Death Study Group
48. Poliovaccine vires in the cerebrospinal fluid after oral polio vaccination
49. Poliovirus vaccination in an infant with hypogammaglobulinaemia
50. Vaccine-associated poliovirus meningitis in children with ventriculoperitoneal shunts
51. Incidence of Guillain-Barre syndrome during a nationwide oral poliovirus vaccine campaign
52. Cluster of childhood Guillain-Barre cases after an oral poliovaccine campaign
53. Epidemiology of Guillain-Barre syndrome in children: Relationship of oral polio vaccine administration to occurrence
54. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barre syndrome
55. Congenital malformations and oral poliovirus vaccination during pregnancy
56. Oral polio vaccination during pregnancy: No increase in the occurrence of congenital malformations
57. Congenital anomalies after oral poliovirus vaccination during pregnancy
58. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease
59. Paralytic poliomyelitis in England and Wales 1970-84
60. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91
61. Vaccine-associated paralytic poliomyelitis among immunodeficient persons
62. Prolonged poliovirus excretion in an immunodeficient persons with vaccine-associated paralytic poliomyelitis
63. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine: A risk factor for vaccine-associated paralytic poliomyelitis
64. Vaccine-associated paralytic poliomyelitis in the United States: No evidence of elevated risk after simultaneous intramuscular injections of vaccine
65. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy
66. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants
67. Haemophilus B. conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: Recommendations of the Immunization Practices Advisory Committee (ACIP)
68. Recommendations for use of Haemophilus B. conjugate vaccines and a combined diphtheria, tetanus, pertussis, and haemophilus B vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
69. Safety of Haemophilus influenzae conjugate vaccine in children born to HIV-1 infected mothers: Kigali (Rwanda), 1992-1994
70. Effect of Haemophilus influenzae type b immunization on HIV viremia in HIV-seropositive adults
71. Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: An analysis after 1 year of marketing
72. Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine
73. A day care-based study of the efficacy of Haemophilus b polysaccharide vaccine
74. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota
75. Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide-diphtheria toxoid conjugate vaccine in adults
76. Recombinant hepatitis B vaccination of neonates and infants: Emerging safety data from the Vaccine Adverse Event Reporting System (VAERS)
77. Comparative safety of two recombinant hepatitis B vaccines in children: Data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)
78. Assessment of a universal, school-based hepatitis B vaccination program
79. The development of rheumatoid arthritis after recombinant hepatitis B vaccination
80. Polyarthritis associated with hepatitis B vaccination
81. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons
82. Infectious arthritis
83. Arthritis after hepatitis B vaccination
84. Reactive arthritis after hepatitis B vaccination: Case report questions cross reacting antigenic determinants between infecting agents and HLA-B27
85. A new case of reactive arthritis after hepatitis B vaccination
86. Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination
87. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination
88. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype
89. MR imaging in a case of postvaccination myelitis
90. Bilateral retrobulbar optic neuritis with hepatitis B vaccination
91. Serious hepatitis B vaccine adverse reactions, are they immune-mediated?
92. Major adverse reaction to yeast-derived hepatitis B vaccines: A review
93. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity
94. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
95. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine
96. Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board
97. Visual loss and eosinophilia after recombinant hepatitis B vaccine
98. Mental nerve neuropathy as a result of hepatitis B vaccination
99. Hepatitis B vaccine side-effect
100. Occlusion of central retinal vein after hepatitis B vaccination
101. Erythema nodusum and Takayasu's arteritis after immunization with plasma derived hepatitis B vaccine
102. Leucoencephalitis after recombinant hepatitis B vaccine
103. Cryoglobulinemia after hepatitis B vaccination
104. Liver dysfunction and DNA antibodies after hepatitis B vaccination
105. A case of severe cytolysis after hepatitis B vaccination
106. Thrombocytopenic purpura after recombinant hepatitis B vaccine
107. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine
108. Hair loss after routine immunizations
109. Hepatitis and hepatitis immunisation
110. Alleged link between hepatitis B vaccine and chronic fatigue syndrome
111. Measles
112. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine
113. Safe administration of the measles vaccine to children allergic to eggs
114. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin
115. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines
116. Vaccination against rubella of susceptible schoolgirls in Reading
117. Absence of an association between rubella vaccination and arthritis in underimmune postpartum women
118. A search for persistent rubella virus infection in persons with chronic symptoms after rubella and rubella immunization and in patients with juvenile rheumatoid arthritis
119. Risk of chronic arthropathy among women after rubella vaccination
120. Randomised doubleblind placebo-controlled study on adverse effects of rubella immunisation in seronegative women
121. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: An analysis of the Vaccine Safety Datalink (VSD) project
122. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children
123. Measles vaccination and Guillain-Barre syndrome
124. Changing character of subacute sclerosing panencephalitis in the United States
125. Measles
126. The national childhood encephalopathy study: A report on 1000 cases of serious neurological disorders in infants and young children from the NCES research team
127. Measles vaccination and neurological events
128. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: A review of claims submitted to the National Vaccine Injury Compensation Program
129. Vaccines and Guillain-Barre syndrome
130. Adverse events following immunization
131. Evidence of persistent measles infection in Crohn's disease
132. Crohn's disease after in-utero measles exposure
133. Measles vaccines: A review of adverse events
134. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease
135. Autism and measles, mumps and rubella vaccine: No epidemiological evidence for a causal association
136. A case-control study of measles vaccination and inflammatory bowel disease
137. Absence of measles viral genomic sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction
138. Measles virus RNA is not detected in inflammatory bowel disease using hybrid capture and reverse transcription followed by the polymerase chain reaction
139. Measles vaccination and inflammatory bowel disease
140. Measles vaccination as a risk factor for inflammatory bowel disease
141. Measles vaccination as a risk factor for inflammatory bowel disease
142. Measles vaccination as a risk factor for inflammatory bowel disease
143. Vaccine adverse events: Causal or coincidental
144. Thrombocytopenia after immunization with measles vaccines: Review of the vaccine adverse events reporting system (1990 to 1994)
145. Purpura in congenital and acquired rubella
146. Exacerbation of chronic thrombocytopenic purpura following measlesmumps-rubella immunization
147. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination
148. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura
149. Vaccine adverse events in the new millenium: Is there reason for concern?
150. Safety of vaccinations: Miss America, the media, and public health
151. Vaccine safety: Current and future challenges
152. Immunization registries in the United States: Implicatons for the practice of a public health in a changing healthcare system
153. Genetic epidemiology